By Adria Calatayud

AstraZeneca PLC (AZN.LN) said Wednesday that it will assume sole responsibility for developing, manufacturing and commercializing Ironwood Pharmaceuticals Inc.'s (IRWD) Linzess drug in China after amending a collaboration agreement.

The FTSE 100-listed company said Cambridge, Mass.-based biotech company Ironwood will no longer be involved in the research and development or the commercialization of Linzess, a treatment for patients with irritable bowel syndrome with constipation, and that manufacturing responsibility will also be transferred to AstraZeneca.

The two companies entered into a collaboration pact in 2012, AstraZeneca said. Under the original agreement, both companies were jointly responsible for strategic oversight of the development and commercialization of Linzess in China, while AstraZeneca had primary responsibility for local operational execution.

Linzess was approved by China's National Medical Products Administration for adults with irritable bowel syndrome with constipation in January and is expected to be launched later this year, AstraZeneca said.

Write to Adria Calatayud at adria.calatayudvaello@dowjones.com

(END) Dow Jones Newswires

September 18, 2019 02:31 ET (06:31 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Astrazeneca